Lab literacy

Peptide testing:
what HPLC shows

The purity percentage on almost every peptide certificate comes from one technique. Here is what it measures, how the number is made, and where it stops.

Short answerLab literacy · 8 min read · Updated 17 Nov 2026

Most peptide purity tests use reversed-phase HPLC. The sample is pumped through a column that separates molecules by how strongly they avoid water, and a UV detector at about 214–220 nm draws a peak for each. Purity is the main peak's share of total peak area. HPLC alone does not confirm identity, amount, counter-ions or endotoxin.

Key takeaways

  • Reversed-phase HPLC separates a peptide from related impurities by hydrophobicity; the UV detector reads the peptide bonds at about 214 nm.
  • Area-% purity assumes every impurity absorbs UV like the main peptide. Tryptophan, for one, absorbs about 30 times more than a peptide bond at 214 nm.
  • The method sets the number: column, solvents, gradient and integration can merge or split peaks.
  • A pure-looking peak can still be the wrong molecule. Identity needs mass spectrometry.

01What reversed-phase HPLC does

High-performance liquid chromatography pushes a dissolved sample at high pressure through a narrow column. Different molecules travel through it at different speeds, so they leave the column one after another.

In the reversed-phase mode used for peptides, the column is packed with particles carrying a water-repelling surface, commonly C18 chains. The liquid flowing through starts mostly as water with a little acid, such as trifluoroacetic acid (TFA) or formic acid, and the share of an organic solvent such as acetonitrile rises over the run. This rising mix is the gradient. Molecules that avoid water cling to the column longer and come off later.

Peptides that differ by a single amino acid, a missing residue or an oxidised side chain usually differ slightly in hydrophobicity. That is why the technique can pull a target peptide apart from most of the by-products of its synthesis.

02What the UV trace shows

As molecules leave the column they pass a UV detector, usually set between 210 and 220 nm. At these wavelengths the peptide bond itself absorbs light, so almost every peptide is visible. The result is the chromatogram: time on the horizontal axis, absorbance on the vertical axis, one peak per separated component.

The peaks are not equal reporters. A 2007 study measured absorbance at 214 nm for each amino acid and for the peptide bond. Tryptophan absorbed about 30 times more than a peptide bond; phenylalanine, tyrosine and histidine about six times more; most other residues much less. A by-product that lost a tryptophan, or gained one, will draw a peak that is smaller or larger than its true share.

Retention time

When a peak leaves the column. Useful for comparing runs on the same method, not proof of identity.

Peak area

The area under each peak. Purity is calculated from these areas, not from peak height.

Baseline

The line the peaks rise from. Where the software draws it changes every area.

03How area-% purity is calculated

The software integrates each peak above a reporting threshold, adds the areas, and divides the main peak by the total.

Purity (area %) = main peak area ÷ sum of all integrated peak areas × 100. Illustration only, not from any real sample: a main peak of 980 area units with side peaks of 12 and 8 gives 980 ÷ 1,000 × 100 = 98.0%.

Three assumptions sit inside that number. Every impurity absorbs UV about as strongly as the main peptide. Every impurity separated from the main peak instead of hiding under it. And everything in the vial both absorbed at that wavelength and came off the column during the run. Water and inorganic salts fail the last test, which is why purity says nothing about how much of the powder is peptide. That is net peptide content.

04Why the method and gradient matter

The same sample can give different purity figures on different methods. In a 2018 Waters application note screening columns for synthetic-peptide impurities, the separation of the peptide bivalirudin changed with the column and with the acid or buffer in the mobile phase. A steep, short gradient can push close impurities into the main peak and raise the number.

Some impurities are hard to separate at all. A 2014 review of related impurities in peptide medicines lists deletion and insertion sequences, diastereomers from racemisation during synthesis, leftover protecting groups, oxidation products, dimers, and degradation products such as pyroglutamate and succinimide forms. A diastereomer has the same mass and nearly the same hydrophobicity as the target. In a second Waters note, impurities co-eluting with the main peptide peak were only found by mass spectrometry.

The validation guideline used by regulators, ICH Q2(R2), says specificity can be shown by absence of interference or by comparing with an orthogonal procedure, and that where one procedure does not discriminate enough, two or more should be combined. For a peptide, HPLC with mass spectrometry is that combination.

  • A credible report names the column, the mobile phases, the gradient, the flow, the wavelength and the run time.
  • A purity figure with no method and no trace cannot be checked or repeated.

05What HPLC can't tell you

QuestionDoes area-% HPLC answer it?What does
Is it the right molecule?No. A wrong peptide can be pure.Mass spectrometry
How many mg of peptide are in the vial?No. Area % is a ratio.Net peptide content, or a quantitative assay against a characterised reference standard
How much TFA or acetate is present?NoCounter-ion analysis, such as ion chromatography
How much water is in the powder?NoWater content, such as Karl Fischer titration
Are there aggregates?Not reliablySize-exclusion chromatography
Is there bacterial endotoxin, or anything alive?NoEndotoxin and sterility tests

FDA made the same point in its July 2026 advisory-committee briefing on BPC-157. One certificate submitted to it listed impurity totals without identifying the impurities, so FDA called the impurity profile unclear; another reported purity only; and a literature search found that most BPC-157 certificates carry only a purity result.

06Reading a chromatogram, step by step

1
Match the document

Batch number, compound and test date agree with the vial and the rest of the certificate.

2
Read the method block

Column, mobile phases, gradient, wavelength. No method, no comparison.

3
Find the main peak

One tall peak with its retention time and area listed in the peak table.

4
Look at its shape

A shoulder, a split top or a long tail can mean something is hiding underneath.

5
Check the peak table

Every visible peak is listed, the areas add up to the stated purity, and the baseline is drawn under the peaks rather than through them.

6
Check the whole run

The trace covers the full gradient, so late-eluting impurities had a chance to appear.

7
Pair it with identity

A mass spectrometry result for the same lot confirms the main peak is the intended peptide.

Plain-English summary of analytical chemistry sources and regulator documents, checked 17 November 2026. Not legal or medical advice.

RefSources

  1. Aguilar MI. Reversed-phase high-performance liquid chromatography. Methods in Molecular Biology 251:9–22, 2004. pubmed.ncbi.nlm.nih.gov/14704435/
  2. Kuipers BJ, Gruppen H. Prediction of molar extinction coefficients of proteins and peptides using UV absorption of the constituent amino acids at 214 nm. J Agric Food Chem 55:5445–5451, 2007. pubmed.ncbi.nlm.nih.gov/17539659/
  3. D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal 101:2–30, 2014. pubmed.ncbi.nlm.nih.gov/25044089/
  4. ICH. Q2(R2) Validation of analytical procedures, section 3.1 Specificity/Selectivity. Guideline, 2023. database.ich.org/sites/default/files/ICH_Q2%28R2%29_Guidelin…
  5. Waters. Synthetic peptide impurity analysis on Waters reversed-phase columns. Application note, 2018. www.waters.com/nextgen/en/library/application-notes/2018/syn…
  6. Waters. Synthetic peptide characterization and impurity profiling using a compliance-ready LC-HRMS workflow. Application note, 2018. www.waters.com/nextgen/gb/en/library/application-notes/2018/…
  7. FDA. Briefing Document, Pharmacy Compounding Advisory Committee, 23–24 July 2026 (BPC-157-related bulk drug substances). Advisory committee briefing, 2026. www.fda.gov/media/193343/download

Plain-English summary of public sources, not legal or medical advice. Last checked 17 Nov 2026.

Questions

What does 99% pure by HPLC mean?

That the main peak made up 99% of the UV peak area the method detected. It is not the share of the powder's weight, and it does not confirm the peak is the right peptide.

Why 214 nm?

The peptide bond absorbs UV around 210–220 nm, so nearly every peptide and peptide by-product shows up there, whatever its sequence.

Can two labs get different purity for the same vial?

Yes. Different columns, gradients and integration settings can separate or merge impurities differently. Compare numbers only when the method is stated.

Can HPLC detect a fake or wrong peptide?

Not on its own. A wrong peptide can give a single clean peak. Mass spectrometry, ideally coupled to the same HPLC run, confirms identity.

Is a higher purity number always better?

Not on its own. A high figure from a method that merges peaks can say less than a slightly lower figure from a method that separates them. Read the number with the method and the identity result.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page
Every batch has a public lab report. Look it up by the batch number on the vial. Batch COA lookup